One of the missions of the Food and Drug Administration (Silver Spring, Maryland) is to protect the public health by assuring the safety, efficacy, and security of human drugs.1 According to Food and Drug Administration guidance, new drugs can be approved as long as they show efficacy compared to placebo, even if there are already drugs approved and available that have been deemed effective.2 Exparel (Pacira Biosciences, Inc., USA), an extended release liposomal formulation of bupivacaine, first approved by the Food and Drug Administration in 2011 for surgical site infiltration, was approved under these circumstances. In this issue, two articles review 10 yr of research on the clinical effectiveness of liposomal bupivacaine. Ilfeld et al.3 provide an extensive narrative review of published randomized controlled trials, and Hussain et al.4 conducted a...
Skip Nav Destination
Article navigation
February 2021
Editorial|
February 2021
Liposomal Bupivacaine: Effective, Cost-effective, or (Just) Costly?
From Harvard Medical School, Cambridge, Massachusetts, and Boston Children’s Hospital, Boston, Massachusetts.
This editorial accompanies the articles on pp. 147 and 283.
Accepted for publication December 1, 2020.
Address correspondence to Dr. McCann: mary.mccann@childrens.harvard.edu
Anesthesiology February 2021, Vol. 134, 139–142.
Connected Content
Citation
Mary Ellen McCann; Liposomal Bupivacaine: Effective, Cost-effective, or (Just) Costly?. Anesthesiology 2021; 134:139–142 doi: https://doi.org/10.1097/ALN.0000000000003658
Download citation file:
Sign in
ASA members enjoy complimentary access to ASA publications, as well as a variety of educational resources. Join today!
ASA Members and Registered Users
Sign InInstitutional Administrators
Admin PortalPay-Per-View Access
$35.00
2,173
Views
0
Citations
Citing articles via
Most Viewed
Related Articles
Perineural Liposomal Bupivacaine Is Not Superior to Nonliposomal Bupivacaine for Peripheral Nerve Block Analgesia: A Systematic Review and Meta-analysis
Anesthesiology (February 2021)
Liposomal Bupivacaine: Extended Duration Nerve Blockade Using Large Unilamellar Vesicles that Exhibit a Proton Gradient
Anesthesiology (September 1996)
Liposomal Bupivacaine Does Not Reduce Inpatient Opioid Prescription or Related Complications after Knee Arthroplasty: A Database Analysis
Anesthesiology (October 2018)
Liposome Bupivacaine Femoral Nerve Block for Postsurgical Analgesia after Total Knee Arthroplasty
Anesthesiology (June 2016)